The size of the Asia Pacific acne drugs market in 2020 was worth USD 1.84 billion and this value is further projected to grow at a CAGR of 6.8% from 2022 to 2027 and be worth USD 2.75 billion by 2027 from USD 1.98 billion in 2022.
Factors such as Lack of sleep, high intake of smoking and alcohol consumption, misusage of drugs, emotional and work-related stress are propelling the acne drugs market in the APAC region. According to the Global Burden of Disease Study, acne vulgaris affects nearly 85% of people aged 12-25 years. The increasing demand for minimally invasive cosmetic treatment procedures is mounting remarkably. Escalating demand for brisk treatments and swift results are projected to drive the need for equipment-based procedures like laser treatments. In addition, rising awareness of acne issues among the single and consciousness regarding the present and upcoming treatments, advanced technologies, and augmenting per capita income motivating the customers in spending more on personal care are anticipated to boost the demand for acne drugs in this region.
The usability of alternatives for acne drugs and therapies served by local players, lack of experienced and skilled dermatologists is predicted to restrain the market growth. In addition, the rising demand for self-medication without a doctor’s prescription and the significance of substitute therapies for nursing acne have been obstructing the sales of branded acne products.
This research report on the Asia Pacific Acne Drugs Market has been segmented & sub-segmented into the following categories:
By Route of Administration:
By Drug Class:
The Asia-Pacific market for acne drugs is anticipated to have rapid growth in the global market in terms of revenue because of common skin diseases and conditions like abnormal hormone growth, high intake of carbohydrates, massive consumption of junk food, and excessive intake of fat creating foods.
The Indian acne drugs market is anticipated to expand at 9.2% CAGR during the forecast period. There are around 200-300 million acne sufferers, finally aiding the market growth in India. In addition, the market is attributed to the growing demand of the population in expending on facial.
The Chinese acne drugs market is expected to lead the APAC market over the forecast period. Increase in many product launches, growing demand for acne therapies, and uplift in healthcare expenses and awareness relevant to newly enhanced therapies that can substitute conventional acne treatment in this region. Rising behavior and unhealthy eating habits, and increasing income bolstered market growth during the analysis period. Moreover, the accessibility of experienced and knowledgeable dermatologists involving the patients virtually in treatment designing is anticipated to add fuel to the development of acne treatment in terms of income. India and China are expected to have rapid growth in the region.
KEY MARKET PLAYERS:
Some of the major companies dominating the Asia Pacific acne drugs market by their products and services include Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., and Daiichi Sankyo Company, Ltd.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org